Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:RXDX

Prometheus Biosciences (RXDX) Stock Price, News & Analysis

Prometheus Biosciences logo

About Prometheus Biosciences Stock (NASDAQ:RXDX)

Advanced Chart

Key Stats

Today's Range
$199.92
$199.92
50-Day Range
$192.50
$199.92
52-Week Range
$23.27
$199.98
Volume
N/A
Average Volume
913,102 shs
Market Capitalization
$9.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.

Receive RXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prometheus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RXDX Stock News Headlines

Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.
Prometheus Biosciences (NASDAQ: RXDX)
See More Headlines

RXDX Stock Analysis - Frequently Asked Questions

Prometheus Biosciences, Inc. (NASDAQ:RXDX) released its quarterly earnings data on Tuesday, May, 9th. The biopharmaceutical company reported ($0.86) earnings per share for the quarter, beating analysts' consensus estimates of ($0.92) by $0.06. The business's revenue for the quarter was down 71.8% on a year-over-year basis.

The following companies are subsidiaries of Prometheus Biosciences: Prometheus Laboratories Inc..

Prometheus Biosciences (RXDX) raised $126 million in an initial public offering (IPO) on Friday, March 12th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Prometheus Biosciences investors own include Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), Visa (V) and Moderna (MRNA).

Company Calendar

Last Earnings
5/09/2023
Today
5/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:RXDX
Fax
N/A
Employees
97
Year Founded
1995

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-141,750,000.00
Net Margins
-3,768.76%
Pretax Margin
-3,768.76%

Debt

Sales & Book Value

Annual Sales
$6.81 million
Price / Cash Flow
N/A
Book Value
$16.12 per share
Price / Book
12.40

Miscellaneous

Free Float
46,187,000
Market Cap
$9.56 billion
Optionable
Not Optionable
Beta
-0.49

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:RXDX) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners